U.S. Markets close in 56 mins.

La Jolla Pharmaceutical Company (LJPC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
30.05-0.31 (-1.02%)
As of 3:03PM EDT. Market open.
People also watch
NBIXINSMLGNDIMMUTGEN

La Jolla Pharmaceutical Company

10182 Telesis Court
6th Floor
San Diego, CA 92121
United States
858-207-4264
http://www.lajollapharmaceutical.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees105

Key Executives

NameTitlePayExercisedAge
Dr. George F. Tidmarsh M.D., Ph.D.Chief Exec. Officer, Pres, Sec. and Director826.15kN/A57
Mr. Dennis M. MulroyChief Financial Officer467.98kN/A62
Ms. Jennifer A. Carver MBAChief Operating Officer482.38kN/A63
Dr. Lakhmir S. Chawla M.D.Chief Medical Officer584.44kN/A46
Mr. James M. RolkeChief Scientific OfficerN/AN/A48
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

Corporate Governance

La Jolla Pharmaceutical Company’s ISS Governance QualityScore as of May 1, 2017 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.